Write in a clean editor, then format for Endocrinology Diabetes and Metabolism Case Reports in one click — DocuGuru applies the official Wiley template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Endocrinology Diabetes and Metabolism Case Reports is a peer-reviewed journal published by Wiley, covering Pituitary Gland Disorders and Treatments, Adrenal and Paraganglionic Tumors, Adrenal Hormones and Disorders.
| Publisher | Wiley |
|---|---|
| Reference style | Author–year (Chicago) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Endocrinology Diabetes and Metabolism Case Reports 12 (3): 45–58.
Formats any DOI in Endocrinology Diabetes and Metabolism Case Reports style. No sign-up. |
| Publishes research in | Pituitary Gland Disorders and Treatments Adrenal and Paraganglionic Tumors Adrenal Hormones and Disorders Thyroid Disorders and Treatments Thyroid Cancer Diagnosis and Treatment |
| ISSN | 2052-0573 |
| Citation impact (2-yr) | 0.75 |
| h-index | 31 |
| i10-index | 259 |
| Total citations | 7,872 |
| Article processing charge | $612 |
| Open access | Yes |
| Top institutions publishing here | Diabetes Australia |
| Journal website | edm.bioscientifica.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Euglycemic diabetic ketoacidosis (EDKA) is a clinical triad comprising increased anion gap metabolic acidosis, ketonemia or ketonuria and normal blood glucose levels <200 mg/dL. This condition is a diagnostic challenge as euglycemia masquerades the underlying diabetic ketoacidosis. Thus, a high clinical suspicion is warranted, and other diagnosis ruled out. Here, we present two patients on…
Checkpoint inhibitors, such as ipilimumab and pembrolizumab, have transformed the prognosis for patients with advanced malignant melanoma and squamous non-small-cell lung cancer, and their use will only expand as experience is gained in a variety of other malignancies, for instance, renal and lymphoma. As the use of checkpoint inhibitors increases, so too will the incidence…
UNLABELLED: Type 1 pseudohypoaldosteronism (PHA) is a rare heterogeneous group of disorders characterised by resistance to aldosterone action. There is resultant salt wasting in the neonatal period, with hyperkalaemia and metabolic acidosis. Only after results confirm isolated resistance to aldosterone can the diagnosis of type 1 PHA be confidently made. Type 1 PHA can be…
SUMMARY: Programmed cell death protein 1/programmed cell death protein ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen 4/B7 (CTLA-4/B7) pathways are key regulators in T-cell activation and tolerance. Nivolumab, pembrolizumab (PD-1 inhibitors), atezolizumab (PD-L1 inhibitor) and ipilimumab (CTLA-4 inhibitor) are monoclonal antibodies approved for treatment of several advanced cancers. Immune checkpoint inhibitors (ICIs)-related hypophysitis is described…
UNLABELLED: Neonatal severe hyperparathyroidism (NSHPT) is a rare disorder caused by inactivating calcium-sensing receptor (CASR) mutations that result in life-threatening hypercalcemia and metabolic bone disease. Until recently, therapy has been surgical parathyroidectomy. Three previous case reports have shown successful medical management of NSHPT with cinacalcet. Here we present the detailed description of two unrelated patients…
